Chimeric Therapeutics is trading 8.33% down at A$0.01 after no verified company-specific announcement was identified for September 2, 2026.
- The latest material update, dated August 19, 2026, disclosed discontinued CHM-2101 enrolment following dose-limiting toxicities, cost reductions, funding uncertainty, and a planned in-vivo development pathway.
- Trading appears volatile after recent sharp daily swings, but the precise catalyst remains unclear.